Drug Compounders File Lawsuit Against FDA Over Wegovy and Ozempic Shortage List Removal

In a significant legal challenge, drug compounders have sued the U.S. Food and Drug Administration (FDA) over its recent decision to remove Wegovy and Ozempic from the official shortage list. This lawsuit, filed in Fort Worth, Texas, claims that the FDA's finding—asserting that there is no longer a shortage of the active ingredient semaglutide—is "arbitrary and capricious."

The Outsourcing Facilities Association and FarmaKeio Custom Compounding argue that this removal will severely limit their ability to produce and sell more affordable compounded versions of these popular weight-loss and diabetes medications. Many patients who struggle to afford brand-name drugs rely on these lower-cost alternatives.

The FDA's action follows a trend of patients turning to compounding pharmacies due to ongoing difficulties in accessing Wegovy and Ozempic. Both drugs have been shown to facilitate significant weight loss, with Wegovy helping patients lose up to 15% of their body weight on average.

This lawsuit is not the first of its kind; it follows a similar complaint regarding the removal of tirzepatide, the active ingredient in Eli Lilly's competing drugs, Zepbound and Mounjaro. The previous case is still pending, highlighting a growing tension between the FDA and the compounding industry.

The FDA has given a 60- to 90-day grace period for compounding pharmacies before enforcement actions will begin, but the outcome of this lawsuit could have far-reaching implications for drug availability and pricing in the U.S. market. As the situation develops, the compounders are seeking to block the FDA's decision, advocating for continued access to these essential medications.